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Background
Single case reports have reported neurological symptoms
or cerebral imaging abnormalities in linear scleroderma of
the face (LSF). Aim of the study was to investigate the fre-
quency and clinical features of CNS involvement in a large
cohort of patients with LSF.
Methods
Patients included in the JUvenile Scleroderma Interna-
tional (JUSI) database of PRES with LSF were evaluated.
Clinical and laboratory information were analyzed in
order to define frequency, type, timing of onset and pos-
sible risk factors of CNS involvement.
Results
121 patients with LSF, followed at 12 centers entered the
study. F:M ratio was 2, 1:1, mean age at onset 5, 8 years.
Among 77 patients whose we obtained complete clinical
and instrumental updated documentation (MRI, CT scan
and EEG), 46 (59.7%) had CNS involvement. 33 (42.9%)
presented with symptoms such as epilepsy in 16 (20.8%),
chronic headache in 11 (14.3%), hemiparesis with or w/o
epilepsy in 3 (3.9%) or behavioural disorders in 3 (3.9%).
Five patients (15.1%) had seizures before the onset of the
skin changes, 39.4% presented neurologic symptoms by
the first year and 84,8% by 5 years since the disease onset.
13 asymptomatic patients presented only EEG or cerebral
imaging abnormalities. All these findings were ipsilateral
to the skin lesion. No significant correlation was found
between CNS involvement and autoantibodies, age at
onset, gender, family history for autoimmune diseases
and environmental factors.
Conclusion
LSF is frequently associated with CNS abnormalities. A
careful clinical and instrumental evaluation should be rec-
ommended for every patient at onset and during the fol-
low-up.
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